63 completed, 7 recruiting, 5 unknown, 4 terminated. 27 Phase 4, 24 Phase 1, 13 Phase 2, 13 Phase 3, 6 Not applicable.
Follow fexofenadine: new trials by email Literature Review of fexofenadine trials Research Report on fexofenadine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mast Cell Treatment in Post-tick Bite Illness (PTBI) Ketotifen, fexofenadine, Cromolyn Sodium - Tick Bites, Mast Cell Activation Disorders | Phase 2 | Not yet recruiting | University of North Carolina, Chapel Hill | 50 | 2027-01-01 | 2026-11-09 |
| A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin KarXT, Midazolam, Fexofenadine - Healthy Volunteers | Phase 1 | Completed | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 62 | 2025-09-29 | 2026-07-22 |
| Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above Fexofenadine HCL and pseudoephedrine HCL - Rhinitis Allergic | Phase 4 | Completed | Sanofi | 203 | 2025-06-15 | 2026-02-17 |
| Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment Experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg), Placebo - Cold, Flu Symptom | Phase 3 | Completed | Eurofarma Laboratorios S.A. | 567 | 2025-03-26 | 2026-10-26 |
| The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction Fexofenadine 60 Mg Oral Tablet, Placebo - Zhejiang University | Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2804 | 2025-01-27 | 2026-08-07 |
| Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial Fexofenadine Hydrochloride, Placebo - ST-segment Elevation Myocardial Infarction (STEMI) | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 160 | 2025-01-20 | 2026-09-16 |
| Fexofenadine as Adjuvant Therapy in Parkinson Disease Levodopa/carbidopa, Fexofenadine - Parkinson Disease | Phase 2 / Phase 3 | Recruiting | Tanta University | 46 | 2024-12-10 | 2026-01-21 |
| Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis Fexofenadine, Gabapentin - Uremic Pruritus, Chronic Kidney Disease-associated Pruritus | Phase 4 | Completed | Tanta University | 60 | 2024-07-01 | 2025-04-27 |
| Effect of Aerobic Exercise with Blood Flow Restriction on Post-exercise Hypotension in Young Adults: the Role of Histamine Receptors H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC) - Prehypertension (elevated Blood Pressure) or Hypertension | Not applicable | Completed | California Baptist University | 10 | 2024-04-01 | 2024-10-08 |
| Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers AV078, Placebo, Itraconazole - Healthy Participants | Phase 1 | Completed | Aeovian Pharmaceuticals, Inc. | 89 | 2024-01-31 | 2025-03-26 |
| A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme AGALSIDASE BETA (GZ419828), Acetaminophen, Diphenhydramine - Fabry's Disease | Phase 4 | Completed | Sanofi | 8 | 2023-11-10 | 2025-10-21 |
| The Role of Histamine in Muscle Protein Synthesis Following Resistance Training Placebo, H1 blockade: Telfast: 180mg Fexofenadine, Resistance training - Histamine | Not applicable | Recruiting | University Ghent | 50 | 2023-09-01 | 2023-12-13 |
| A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants BMS-986419, Caffeine, Bupropion - Healthy Volunteers | Phase 1 | Completed | Bristol-Myers Squibb | 22 | 2023-06-29 | 2023-10-30 |
| Excipient Effect on Drug Absorption in Humans Fexofenadine Hydrochloride without sodium lauryl sulfate, Fexofenadine Hydrochloride with sodium lauryl sulfate - The Impact of Excipients on Drug Absorption | Early Phase 1 | Completed | University of California, San Francisco | 12 | 2023-01-31 | 2025-11-18 |
| A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis Fexofenadine, Placebo - Seasonal Allergic Rhinitis | Phase 3 | Completed | Opella Healthcare Group SAS, a Sanofi Company | 95 | 2023-01-23 | 2025-09-09 |
| Fexofenadine in Patients With Active Rheumatoid Arthritis Fexofenadine, Placebo - Rheumatoid Arthritis | Phase 1 / Phase 2 | Recruiting | October 6 University | 80 | 2022-06-01 | 2025-07-31 |
| Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) Dupilumab, Placebo, Fexofenadine (loratadine if not available) - Pruritus | Phase 3 | Recruiting | Sanofi | 284 | 2022-02-15 | 2026-10-15 |
| Role of Antihistaminic in Acute Renal Colic Prevent Pain Recurrence and Expulsion of Ureteric Stone ≤ 1cm Tamsulosin Hcl 0.4Mg Cap, fexofenadine 180 mg Oral tablet - Renal Colic, Ureter Stone | Unknown | Assiut University | 100 | 2021-11-30 | 2021-12-09 | |
| Effect of Antihistamines on Ureteral Stent-Related Symptoms Fexofenadine Hcl 180Mg Tab, Placebo - Nephrolithiasis | Phase 2 | Completed | Columbia University | 78 | 2021-06-29 | 2025-07-16 |
| Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis Rituximab, Ocrelizumab, Fexofenadine - Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | Phase 3 | Active not recruiting | Copenhagen University Hospital, Rigshospitalet | 600 | 2021-04-28 | 2026-08-17 |
Showing 20 of 81. Sign in to see all of them.
Rhinitis, Allergic, Seasonal (11) · Rhinitis, Allergic (9) · Pruritus (4) · Asthma (3) · Rhinitis, Allergic, Perennial (3) · Hypertension (2) · Rhinitis (2) · Arthritis, Rheumatoid (1) · Carcinoma, Non-Small-Cell Lung (1) · Chronic Urticaria (1) · Common Cold (1) · Depression (1) · Dermatitis, Atopic (1) · Diabetic Nephropathies (1) · Edema (1)
Sanofi (17) · Dr. Reddy's Laboratories Limited (5) · Organon and Co (5) · Pfizer (3) · Tanta University (3) · GlaxoSmithKline (2) · Jules Desmeules (2) · Mylan Pharmaceuticals Inc (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Teva Pharmaceuticals USA (2) · University Ghent (2) · University of North Carolina, Chapel Hill (2) · Aeovian Pharmaceuticals, Inc. (1) · Alexion Pharmaceuticals, Inc. (1) · Amgen (1)
United States (29) · Canada (6) · Japan (5) · Egypt (4) · India (4) · South Korea (4) · China (3) · France (3) · Hungary (3) · Poland (3) · Switzerland (3) · Belgium (2) · Costa Rica (2) · Germany (2) · Guatemala (2)
Phyllis Diener (6) · Dr. Dharmesh Domadia (2) · James D Carlson, Pharm. D. (2) · Thomas S Clark, M.D. (2) · Ahmed M Hussein, PhD (1) · Benoit Girard, M.D (1) · Carmela Pagunsan (1) · Celia Lloret-Linares, MD, PhD (1) · Dal-Sik Kim, PhD, MD (1) · Daniele Santini, MD, PhD (1)
PMID 11756098, PMID 12072644, PMID 16913264, PMID 17011944, PMID 17102958, PMID 19943178, PMID 22266271, PMID 22995650, PMID 23018163, PMID 23147964, PMID 24018772, PMID 2466358, PMID 24722393, PMID 25024716, PMID 25530364, PMID 27326985, PMID 27495955, PMID 27746690, PMID 27908918, PMID 28709817, PMID 29570971, PMID 30875094, PMID 33283264, PMID 36099211, PMID 37741921, PMID 38447697, PMID 39678124, PMID 39937815, PMID 42775939
2018 (1), 2023 (1)